Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTA-SNA040 in Claudin 18.2-positive Advanced Solid Tumors
NCT07595237Phase 1Recruiting
- Sponsor
- SmartNuclide
- Start
- Nov 2025
- Primary completion
- Nov 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of 177Lu-DOTA-SNA040 in solid tumor (4 arms), sponsored by SmartNuclide. Primary endpoints: Dose-limiting toxicity and Safety and tolerance of 177Lu-DOTA-SNA040. Started Nov 2025; status: recruiting.
02
Drugs
177Lu-DOTA-SNA040
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07595237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595237.